Copyright
©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827
Table 6 Dose adherence to pregabalin 150 mg twice daily during the study period of 8 weeks
Dose adjustment | Number of patients | Percentage of total patients (%) |
Increased to 300 mg twice daily | 3 | 30 |
No change | 7 | 70 |
- Citation: Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827
- URL: https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i4.104827